Vanadium as a tracer of oil pollution in the sediments of Kuwait

Vanadium is important as an indicator of oil pollution since oil is one of the main contributors of vanadium to the environment and because most crude oils contain relatively high concentrations of vanadium (30.6 ± 14.3 mg kg^–1 were measured in nine different Kuwait crudes). If oil has settled to the bottom and biodegradation has taken place, it is obvious that enrichment of vanadium in the sediment may be observed.More than 200 sampling sites were selected in the coastal zone of Kuwait and sediment samples were analyzed for grain size distribution, CaC0₃ content, heavy metals and TOC. The analytical results were normalized by taking into account the natural background levels of vanadium in different sediment fractions.After evaluation of the results, vanadium enrichments of as much as 10 to 77 mg kg^–1 were found at 15 sampling locations and of 1 to 10 mg kg^–1 at many others. The areas of vanadium enrichment in the sediments were located 3–5 km from the shoreline in the areas of wastewater discharges, near oil loading piers and in the shipping channels. There was no correlation between vanadium and TOC indicating that biodegradation of oils had taken place. However, high TOC values in the sediments were determined in the near shore sediments around the outlets.     

Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status

Not all patients with Hodgkin's disease (HD) respond to standard chemotherapy and/or radiation, and hematopoietic stem-cell transplantation has been gaining increasing acceptance in the management of HD. Phase II and, to a lesser extent, phase III studies of high-dose chemotherapy and autologous stem cell transplantation carried out at multiple institutions worldwide have proven the feasibility of the procedure and provided extended progression-free survival (and possibly cure) in a sizable number of patients with relapsed or refractory HD. Prognostic factors have been identified by multiple investigators (with response to chemotherapy being the most impressive one) and may ultimately allow a risk-adapted strategy. While early and late treatment-related morbidity and mortality remains an issue, with current supportive care modalities most patients tolerate this procedure with only minor or manageable complications. Disease recurrence remains a problem in many patients, and this can unfortunately occur as late as six or seven years after a seemingly successful transplant. New chemotherapeutic agents and strategies (such as post-transplant maintenance and possibly immunomodulation) will be required to successfully tackle this issue. Allogeneic stem-cell transplantation from HLA-compatible donors has yielded largely unsatisfactory results in the published studies in the literature, despite favorable results in a small minority of patients. Recently, however, newer approaches and strategies (such as the introduction of reduced-intensity, purine analog-based conditioning regimens and possibly cellular immunotherapy in the form of donor lymphocyte infusions) have provided very encouraging early results and seem to brighten the outlook for this procedure.